glyburide has been researched along with Insulin Resistance in 87 studies
Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide
glyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group.
Insulin Resistance: Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Several studies have demonstrated the decreased insulin resistance (IR) in persons with type 2 diabetes mellitus (T2DM) treated with glimepiride." | 9.30 | The differential influence of glimepiride and glibenclamide on insulin resistance and adiponectin levels in patients with type 2 diabetes. ( Bahtiri, E; Begolli, L; Blaslov, K; Car, N; Emini-Sadiku, M; Haliti, E, 2019) |
| "Measures of β-cell function and insulin sensitivity from an OGTT showed more favorable changes over time with rosiglitazone versus metformin or glyburide." | 9.15 | Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT. ( Aftring, RP; Haffner, SM; Herman, WH; Holman, RR; Kahn, SE; Kravitz, BG; Lachin, JM; Paul, G; Viberti, G; Zinman, B, 2011) |
| "Glimepiride appears to improve insulin resistance and atherosclerotic disorders." | 9.12 | Efficacy of glimepiride on insulin resistance, adipocytokines, and atherosclerosis. ( Ito, S; Koshiba, K; Nakaya, Y; Nomura, M, 2006) |
| "This study compared the effects of 52 weeks' treatment with pioglitazone, a thiazolidinedione that reduces insulin resistance, and glibenclamide, on insulin sensitivity, glycaemic control, and lipids in patients with Type 2 diabetes." | 9.11 | Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes. ( Clausen, J; Eriksson, JW; Halse, J; Herz, M; Johns, D; Konkoy, CS; Madsbad, S; Strand, J; Tan, MH, 2004) |
| "The aim of the present study was to investigate the effect of bezafibrate on insulin sensitivity and insulin secretion in 30 non-obese Japanese type 2 diabetic patients with hypertriglyceridemia (serum triglycerides > 150 mg/dL)." | 9.09 | Effects of bezafibrate on insulin sensitivity and insulin secretion in non-obese Japanese type 2 diabetic patients. ( Doi, K; Fukunaga, A; Fukushima, M; Kishimoto, H; Kitatani, N; Matsuura, T; Nagasaka, S; Nagata, I; Nakai, Y; Nakaishi, S; Okumura, T; Sakai, M; Taniguchi, A; Tokuyama, K; Yamashita, Y, 2001) |
| "Both doses of olanzapine caused pronounced glucose dysregulation and insulin resistance, which were significantly reduced by treatment with metformin and rosiglitazone; however, glucose tolerance did not fully return to control levels." | 7.78 | Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats. ( Barr, AM; Boyda, HN; Hawkes, E; Honer, WG; Jin, CH; Pang, CC; Procyshyn, RM; Tse, L, 2012) |
| "To observe and compare the effect of taurine on contractions of aortic rings isolated from normal (NC) and insulin resistance (IR) Sprague-Dawley rats, and to explore its underlying mechanism(s)." | 7.74 | Effects of taurine on aortic rings isolated from fructose-fed insulin resistance Sprague-Dawley rat are changed. ( Li, J; Liang, Y; Niu, L; Wu, D; Xue, W; Zhang, M, 2008) |
| "Here we investigate the effect of rosiglitazone (RSG), metformin (MET) and glyburide (GLIB) on plasma glucose levels, beta-cell mass, function and insulin sensitivity in 10-week-old diabetic male Zucker diabetic fatty (mZDF) rats using quantitative morphometry and a mathematical model beta-cell mass, insulin and glucose kinetics (betaIG)." | 7.74 | Effect of chronic rosiglitazone, metformin and glyburide treatment on beta-cell mass, function and insulin sensitivity in mZDF rats. ( Atkinson, LL; Benkoczi, C; Finegood, DT; McDonald-Dyck, C, 2008) |
| "Pioglitazone is an insulin-sensitizing agent that has been reported to have anti-arteriosclerotic effects." | 6.71 | Effect of pioglitazone on arteriosclerosis in comparison with that of glibenclamide. ( Anazawa, T; Kanmatsuse, K; Kushiro, T; Tani, S; Watanabe, I, 2005) |
| "Several studies have demonstrated the decreased insulin resistance (IR) in persons with type 2 diabetes mellitus (T2DM) treated with glimepiride." | 5.30 | The differential influence of glimepiride and glibenclamide on insulin resistance and adiponectin levels in patients with type 2 diabetes. ( Bahtiri, E; Begolli, L; Blaslov, K; Car, N; Emini-Sadiku, M; Haliti, E, 2019) |
| "Measures of β-cell function and insulin sensitivity from an OGTT showed more favorable changes over time with rosiglitazone versus metformin or glyburide." | 5.15 | Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT. ( Aftring, RP; Haffner, SM; Herman, WH; Holman, RR; Kahn, SE; Kravitz, BG; Lachin, JM; Paul, G; Viberti, G; Zinman, B, 2011) |
| "Both exenatide and glibenclamide gave a similar improvement of glycemic control, but only exenatide gave improvements of insulin resistance and beta-cell function, giving also a decrease of body weight and of inflammatory state." | 5.14 | Exenatide versus glibenclamide in patients with diabetes. ( Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Franzetti, IG; Gadaleta, G; Maffioli, P; Piccinni, MN; Querci, F; Ragonesi, PD; Salvadeo, SA, 2010) |
| "Glimepiride appears to improve insulin resistance and atherosclerotic disorders." | 5.12 | Efficacy of glimepiride on insulin resistance, adipocytokines, and atherosclerosis. ( Ito, S; Koshiba, K; Nakaya, Y; Nomura, M, 2006) |
| "To investigate the relationship between insulin resistance, postprandial hyperglycemia, postprandial hyperlipidemia, and oxidative stress in type 2 diabetes, changes in postprandial glucose, triglyceride, and nitrotyrosine levels vs baseline after diet loading were examined in type 2 diabetic patients given pioglitazone (PG) or glibenclamide (GB)." | 5.12 | Effects of pioglitazone vs glibenclamide on postprandial increases in glucose and triglyceride levels and on oxidative stress in Japanese patients with type 2 diabetes. ( Itoh, Y; Mori, Y; Obata, T; Tajima, N, 2006) |
| "This study compared the effects of 52 weeks' treatment with pioglitazone, a thiazolidinedione that reduces insulin resistance, and glibenclamide, on insulin sensitivity, glycaemic control, and lipids in patients with Type 2 diabetes." | 5.11 | Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes. ( Clausen, J; Eriksson, JW; Halse, J; Herz, M; Johns, D; Konkoy, CS; Madsbad, S; Strand, J; Tan, MH, 2004) |
| "The aim of the present study was to investigate the effect of bezafibrate on insulin sensitivity and insulin secretion in 30 non-obese Japanese type 2 diabetic patients with hypertriglyceridemia (serum triglycerides > 150 mg/dL)." | 5.09 | Effects of bezafibrate on insulin sensitivity and insulin secretion in non-obese Japanese type 2 diabetic patients. ( Doi, K; Fukunaga, A; Fukushima, M; Kishimoto, H; Kitatani, N; Matsuura, T; Nagasaka, S; Nagata, I; Nakai, Y; Nakaishi, S; Okumura, T; Sakai, M; Taniguchi, A; Tokuyama, K; Yamashita, Y, 2001) |
| "Both doses of olanzapine caused pronounced glucose dysregulation and insulin resistance, which were significantly reduced by treatment with metformin and rosiglitazone; however, glucose tolerance did not fully return to control levels." | 3.78 | Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats. ( Barr, AM; Boyda, HN; Hawkes, E; Honer, WG; Jin, CH; Pang, CC; Procyshyn, RM; Tse, L, 2012) |
| "Glimepiride can rapidly and stably improve glycemic control and lipoprotein metabolism, significantly alleviate insulin resistance and enhance fibrinolytic activity." | 3.76 | Effects of Glimepiride on metabolic parameters and cardiovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus. ( Du, W; Huang, QX; Liu, L; Liu, YH; Xie, XM; Xu, DY; Zhao, SP, 2010) |
| "To observe and compare the effect of taurine on contractions of aortic rings isolated from normal (NC) and insulin resistance (IR) Sprague-Dawley rats, and to explore its underlying mechanism(s)." | 3.74 | Effects of taurine on aortic rings isolated from fructose-fed insulin resistance Sprague-Dawley rat are changed. ( Li, J; Liang, Y; Niu, L; Wu, D; Xue, W; Zhang, M, 2008) |
| "Here we investigate the effect of rosiglitazone (RSG), metformin (MET) and glyburide (GLIB) on plasma glucose levels, beta-cell mass, function and insulin sensitivity in 10-week-old diabetic male Zucker diabetic fatty (mZDF) rats using quantitative morphometry and a mathematical model beta-cell mass, insulin and glucose kinetics (betaIG)." | 3.74 | Effect of chronic rosiglitazone, metformin and glyburide treatment on beta-cell mass, function and insulin sensitivity in mZDF rats. ( Atkinson, LL; Benkoczi, C; Finegood, DT; McDonald-Dyck, C, 2008) |
| "Although the role of insulin sensitivity is not negligible, insulin secretion appears to be the major determinant of diabetic control in overt type 2 diabetic patients who are treated with metformin alone or with a two-drug therapy combining metformin and glyburide." | 3.73 | Insulin secretion and sensitivity as determinants of HbA1c in type 2 diabetes. ( Colette, C; Lapinski, H; Monnier, L; Thuan, JF, 2006) |
| "To determine whether hypoglycemic agents such as sulfonylureas, biguanides and the newly developed insulin sensitizers such as troglitazone, have hypotensive effects in an animal model of non-insulin-dependent diabetes mellitus associated with insulin resistance, male Otsuka Long Evans Tokushima Fatty (OLETF) rats aged 12 weeks were administered following hypoglycemic agents or vehicle by gavage for 26 weeks; glibenclamide (5 mg/kg/day), metformin (100 mg/kg/day) and troglitazone (70 mg/kg/day)." | 3.70 | Troglitazone and metformin, but not glibenclamide, decrease blood pressure in Otsuka Long Evans Tokushima Fatty rats. ( Awata, T; Chen, S; Katayama, S; Kosegawa, I; Negishi, K, 1999) |
| "Insulin tolerance test was done to assess the insulin sensitivity in a group of untreated non insulin dependent diabetic subjects before and after sulfonylurea (tolbutamide, glibenclamide, glipizide) therapy." | 3.68 | Effect of sulphonylurea therapy on insulin sensitivity in non insulin dependent diabetics. ( Dash, RJ; Khandekar, S; Sethi, BK, 1990) |
| "Glyburide and other sulfonylureas consistently enhance receptor binding in cells from patients with non-insulin-dependent diabetes mellitus, whereas no effects and mixed effects have been demonstrated in cells from patients with insulin-dependent diabetes mellitus and in normal cells, respectively." | 3.67 | Dual actions of sulfonylureas and glyburide. Receptor and post-receptor effects. ( Gavin, JR, 1985) |
| " Data are limited regarding the pharmacodynamic effects of metformin and glyburide during pregnancy." | 2.94 | Pharmacodynamics of Glyburide, Metformin, and Glyburide/Metformin Combination Therapy in the Treatment of Gestational Diabetes Mellitus. ( Ahmed, MS; Brown, LM; Brown, Z; Caritis, S; Clark, S; Easterling, TR; Flood Nichols, SK; Haas, DM; Haneline, LS; Hebert, MF; Ma, X; Manuck, TA; Quinney, SK; Ren, Z; Shen, DD; Shireman, LM; Shuster, DL; Thummel, KE; Tita, AT; Venkataramanan, R, 2020) |
| "Pioglitazone was better than glibenclamide in decreasing HbA (1c), FPG, FPI, lipid profile, and in improving inflammatory parameters such as Hs-CRP, and ADN." | 2.76 | Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. ( Bianchi, L; Cicero, AF; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P, 2011) |
| " Women with GDM in whom glyburide treatment has failed may benefit from alternative medication or dosage escalation; however, fetal safety should be kept in mind." | 2.74 | Are we optimizing gestational diabetes treatment with glyburide? The pharmacologic basis for better clinical practice. ( Ahmed, MS; Blough, D; Caritis, SN; Carr, DB; Cobelli, C; Easterling, TR; Hankins, GD; Hebert, MF; Kelly, EJ; Krudys, KM; Ma, X; Mattison, DR; Miodovnik, M; Naraharisetti, SB; Snodgrass, WR; Umans, JG; Unadkat, JD; Vicini, P, 2009) |
| "Pioglitazone treatment resulted in a significant reduction in fasting levels of PI and SPI compared to those of the controls." | 2.73 | Reduced postprandial proinsulinaemia and 32-33 split proinsulinaemia after a mixed meal in type 2 diabetic patients following sensitization to insulin with pioglitazone. ( Al Majali, K; Bailey, CJ; Betteridge, DJ; Cooper, MB, 2008) |
| "No weight gain was observed in patients treated with nateglinide." | 2.72 | Nateglinide with glibenclamide examination using the respiratory quotient (RQ). ( Harada, S; Ito, S; Nakaya, Y; Nomura, M, 2006) |
| "Metabolic syndrome was more frequent and microalbuminuria less frequent in NAC." | 2.72 | A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe. ( Freed, MI; Haffner, S; Heise, MA; Herman, WH; Holman, R; Jones, NP; Kahn, SE; Kravitz, B; Lachin, J; O'Neill, MC; Viberti, G; Zinman, B, 2006) |
| "Type 2 diabetes mellitus is characterized by both insulin deficiency and insulin resistance." | 2.71 | Beneficial effects of a glyburide/metformin combination preparation in type 2 diabetes mellitus. ( Bokhari, SU; Duckworth, WC; Gopal, UM, 2003) |
| "Pioglitazone is an insulin-sensitizing agent that has been reported to have anti-arteriosclerotic effects." | 2.71 | Effect of pioglitazone on arteriosclerosis in comparison with that of glibenclamide. ( Anazawa, T; Kanmatsuse, K; Kushiro, T; Tani, S; Watanabe, I, 2005) |
| "Glyburide treatment of diabetes decreased CRP and did so even though body weight increased." | 2.71 | Adiponectin and C-reactive protein in obesity, type 2 diabetes, and monodrug therapy. ( Bar, RS; Goldner, WS; Haynes, WG; Putz, DM; Sivitz, WI, 2004) |
| " In conclusion, combination treatment with metformin and sulfonylurea is more effective than these drugs alone in improving glycemic control in type 2 diabetes, while also allowing a reduction of the dosage of each drug." | 2.71 | Combination treatment with metformin and glibenclamide versus single-drug therapies in type 2 diabetes mellitus: a randomized, double-blind, comparative study. ( Brun, E; Coppini, A; Gori, M; Moghetti, P; Muggeo, M; Perobelli, L; Spiazzi, G; Tosi, F; Zanolin, E, 2003) |
| " The dosage of hypoglycemic drugs was maintained at a constant level throughout the study." | 2.67 | A high-monounsaturated-fat/low-carbohydrate diet improves peripheral insulin sensitivity in non-insulin-dependent diabetic patients. ( Capaldo, B; Ciardullo, AV; Genovese, S; Giacco, A; Parillo, M; Riccardi, G; Rivellese, AA, 1992) |
| "The usual choice of therapy in NIDDM diabetes, using oral anti-diabetic compounds, insulin or associated treatments, is based on the results of treatment evaluated empirically using glycemic profiles." | 2.67 | [Model of therapeutic programming in NIDDM diabetes]. ( Cortinovis, A; Crippa, A; Romano, E, 1992) |
| "Insulin sensitivity was increased by glibenclamide but not by glipizide." | 2.66 | Pharmacokinetics and metabolic effects of glibenclamide and glipizide in type 2 diabetics. ( Fyhrqvist, F; Groop, L; Groop, PH; Melander, A; Tolppanen, EM; Tötterman, KJ; Wåhlin-Boll, E, 1985) |
| "Insulin resistance is the key in this process because of the inability of insulin to suppress hepatic glucose production, thereby allowing an unopposed glucagon effect." | 2.38 | Effects of glyburide on carbohydrate metabolism and insulin action in the liver. ( Caro, JF, 1990) |
| "to investigate possible beneficial effects of hydroalcoholic extract of SecurigeraSecuridaca seed (HESS) on antioxidant capacity, fibroblast growth factor 21 (FGF21) and insulin resistance in Streptozotocin (STZ)-induced diabetic rats, alone and in combination with glibenclamide." | 1.56 | Effects of Securigera Securidaca seed extract in combination with glibenclamide on antioxidant capacity, fibroblast growth factor 21 and insulin resistance in hyperglycemic rats. ( Alizadeh-Fanalou, S; Azadi, N; Babaei, M; Bahreini, E; Borji, M; Hosseini, A; Malekinejad, H; Nazarizadeh, A; Shojaii, A, 2020) |
| " Meanwhile, in co-treated group, elimination rate constant (Ke) of glibenclamide was reduced while peak plasma concentration (C(max)), area under the plasma concentration vs time curve (AUC(0-14 h)) and elimination half-life (T(1/2Ke)) were increased significantly vs glibenclamide alone administered rats." | 1.35 | Effects of 18alpha-glycyrrhizin on the pharmacodynamics and pharmacokinetics of glibenclamide in alloxan-induced diabetic rats. ( Ao, Y; Chen, J; Peng, RX; Yue, J, 2008) |
| "One hundred and twenty-four consecutive type 2 diabetes patients (mean age, 57." | 1.32 | Beneficial effects of triple drug combination of pioglitazone with glibenclamide and metformin in type 2 diabetes mellitus patients on insulin therapy. ( Chandalia, HB; Fafadia, A; Joshi, SR; Panikar, V; Santvana, C, 2003) |
| "Insulin resistance was produced when the hypoglycemic action of glibenclamide at a dose of 10 mg/kg was almost abolished in rats that received daily injections of long-acting insulin for 15 days." | 1.31 | Less of insulin desensitization in sympathetic nerve terminals from wistar rats with insulin resistance. ( Cheng, JT; Chi, TC; Liu, IM, 2000) |
| "Seventy-five patients with type 2 diabetes participated (mean age (+/- SD), 67 +/- 8 years; body mass index, 25." | 1.30 | Prognostic factors for successful insulin therapy in subjects with type 2 diabetes. ( Menheere, PP; Rondas-Colbers, GJ; Sels, JP; Wolffenbuttel, BH, 1999) |
| "A 60-year-old obese woman with type II diabetes mellitus and hepatomegaly exhibited progression of steatosis to hepatitis and cirrhosis." | 1.29 | Remission of active diabetic hepatitis after correction of hyperglycemia. ( Tak, PP; ten Kate, FJ, 1993) |
| "Insulin sensitivity has been determined in primary nonobese diabetics and subjects with borderline glucose intolerance by a newly devised technique using glucose, insulin, and somatostatin infusion." | 1.26 | Clinical significance of altered insulin sensitivity in diabetes mellitus assessed by glucose, insulin, and somatostatin infusion. ( Harano, Y; Hidaka, H; Izumi, K; Kashiwagi, A; Kobayashi, M; Kosugi, K; Nakano, T; Ohgaku, S; Shigeta, Y; Yasuda, H, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (13.79) | 18.7374 |
| 1990's | 11 (12.64) | 18.2507 |
| 2000's | 35 (40.23) | 29.6817 |
| 2010's | 26 (29.89) | 24.3611 |
| 2020's | 3 (3.45) | 2.80 |
| Authors | Studies |
|---|---|
| Yu, J | 1 |
| Ahn, S | 2 |
| Kim, HJ | 1 |
| Lee, M | 1 |
| Kim, J | 1 |
| Jin, SH | 1 |
| Lee, E | 1 |
| Kim, G | 1 |
| Cheong, JH | 1 |
| Jacobson, KA | 1 |
| Jeong, LS | 1 |
| Noh, M | 1 |
| Alizadeh-Fanalou, S | 1 |
| Babaei, M | 1 |
| Hosseini, A | 1 |
| Azadi, N | 1 |
| Nazarizadeh, A | 1 |
| Shojaii, A | 1 |
| Borji, M | 1 |
| Malekinejad, H | 1 |
| Bahreini, E | 1 |
| Shuster, DL | 1 |
| Shireman, LM | 1 |
| Ma, X | 2 |
| Shen, DD | 1 |
| Flood Nichols, SK | 1 |
| Ahmed, MS | 2 |
| Clark, S | 1 |
| Caritis, S | 1 |
| Venkataramanan, R | 1 |
| Haas, DM | 1 |
| Quinney, SK | 1 |
| Haneline, LS | 1 |
| Tita, AT | 1 |
| Manuck, TA | 1 |
| Thummel, KE | 1 |
| Brown, LM | 1 |
| Ren, Z | 1 |
| Brown, Z | 1 |
| Easterling, TR | 2 |
| Hebert, MF | 2 |
| Pires Mendes, C | 1 |
| Postal, BG | 1 |
| Silva Frederico, MJ | 1 |
| Gonçalves Marques Elias, R | 1 |
| Aiceles de Medeiros Pinto, V | 1 |
| da Fonte Ramos, C | 1 |
| Devantier Neuenfeldt, P | 1 |
| Nunes, RJ | 1 |
| Mena Barreto Silva, FR | 1 |
| Sadri, H | 1 |
| Larki, NN | 1 |
| Kolahian, S | 1 |
| Gao, H | 1 |
| Ho, E | 1 |
| Balakrishnan, M | 1 |
| Yechoor, V | 1 |
| Yallampalli, C | 1 |
| Su, WJ | 1 |
| Peng, W | 1 |
| Gong, H | 1 |
| Liu, YZ | 1 |
| Zhang, Y | 1 |
| Lian, YJ | 1 |
| Cao, ZY | 1 |
| Wu, R | 1 |
| Liu, LL | 1 |
| Wang, B | 1 |
| Wang, YX | 1 |
| Jiang, CL | 1 |
| Yildiz, M | 1 |
| Akcay, T | 1 |
| Aydin, B | 1 |
| Akgun, A | 1 |
| Dogan, BB | 1 |
| De Franco, E | 1 |
| Ellard, S | 1 |
| Onal, H | 1 |
| Emfinger, CH | 1 |
| Yan, Z | 1 |
| Welscher, A | 1 |
| Hung, P | 1 |
| McAllister, W | 1 |
| Hruz, PW | 2 |
| Nichols, CG | 2 |
| Remedi, MS | 2 |
| Emini-Sadiku, M | 1 |
| Car, N | 1 |
| Begolli, L | 1 |
| Blaslov, K | 1 |
| Haliti, E | 1 |
| Bahtiri, E | 1 |
| Derosa, G | 4 |
| Cicero, AF | 4 |
| Franzetti, IG | 3 |
| Querci, F | 3 |
| Carbone, A | 2 |
| Piccinni, MN | 3 |
| D'Angelo, A | 4 |
| Fogari, E | 3 |
| Maffioli, P | 4 |
| Henriksbo, BD | 1 |
| Lau, TC | 1 |
| Cavallari, JF | 1 |
| Denou, E | 1 |
| Chi, W | 1 |
| Lally, JS | 1 |
| Crane, JD | 1 |
| Duggan, BM | 1 |
| Foley, KP | 1 |
| Fullerton, MD | 1 |
| Tarnopolsky, MA | 1 |
| Steinberg, GR | 1 |
| Schertzer, JD | 1 |
| Honda, H | 1 |
| Nagai, Y | 1 |
| Matsunaga, T | 1 |
| Okamoto, N | 1 |
| Watanabe, Y | 1 |
| Tsuneyama, K | 1 |
| Hayashi, H | 1 |
| Fujii, I | 1 |
| Ikutani, M | 1 |
| Hirai, Y | 1 |
| Muraguchi, A | 1 |
| Takatsu, K | 1 |
| Roche, C | 1 |
| Besnier, M | 1 |
| Cassel, R | 1 |
| Harouki, N | 1 |
| Coquerel, D | 1 |
| Guerrot, D | 1 |
| Nicol, L | 1 |
| Loizon, E | 1 |
| Remy-Jouet, I | 1 |
| Morisseau, C | 1 |
| Mulder, P | 1 |
| Ouvrard-Pascaud, A | 1 |
| Madec, AM | 1 |
| Richard, V | 1 |
| Bellien, J | 1 |
| Koupý, D | 1 |
| Kotolová, H | 1 |
| Rudá Kučerová, J | 1 |
| Seino, Y | 1 |
| Kuwata, H | 1 |
| Yabe, D | 1 |
| Choudhary, S | 1 |
| Mourya, A | 1 |
| Ahuja, S | 1 |
| Sah, SP | 1 |
| Kumar, A | 1 |
| Stephen Irudayaraj, S | 1 |
| Christudas, S | 1 |
| Antony, S | 1 |
| Duraipandiyan, V | 1 |
| Naif Abdullah, AD | 1 |
| Ignacimuthu, S | 1 |
| Franco, CCS | 1 |
| Prates, KV | 1 |
| Previate, C | 1 |
| Moraes, AMP | 1 |
| Matiusso, CCI | 1 |
| Miranda, RA | 1 |
| de Oliveira, JC | 1 |
| Tófolo, LP | 1 |
| Martins, IP | 1 |
| Barella, LF | 1 |
| Ribeiro, TA | 1 |
| Malta, A | 1 |
| Pavanello, A | 1 |
| Francisco, FA | 1 |
| Gomes, RM | 1 |
| Alves, VS | 1 |
| Moreira, VM | 1 |
| Rigo, KP | 1 |
| Almeida, DL | 1 |
| de Sant Anna, JR | 1 |
| Prado, MAAC | 1 |
| Mathias, PCF | 1 |
| Xue, W | 1 |
| Zhang, M | 1 |
| Li, J | 1 |
| Wu, D | 1 |
| Niu, L | 1 |
| Liang, Y | 1 |
| Naraharisetti, SB | 1 |
| Krudys, KM | 1 |
| Umans, JG | 1 |
| Hankins, GD | 1 |
| Caritis, SN | 1 |
| Miodovnik, M | 1 |
| Mattison, DR | 1 |
| Unadkat, JD | 1 |
| Kelly, EJ | 1 |
| Blough, D | 1 |
| Cobelli, C | 1 |
| Snodgrass, WR | 1 |
| Carr, DB | 1 |
| Vicini, P | 1 |
| Xu, DY | 1 |
| Zhao, SP | 1 |
| Huang, QX | 1 |
| Du, W | 1 |
| Liu, YH | 1 |
| Liu, L | 1 |
| Xie, XM | 1 |
| Konya, H | 1 |
| Hasegawa, Y | 1 |
| Hamaguchi, T | 1 |
| Satani, K | 1 |
| Umehara, A | 1 |
| Katsuno, T | 1 |
| Ishikawa, T | 1 |
| Miuchi, M | 1 |
| Kohri, K | 1 |
| Suehiro, A | 1 |
| Kakishita, E | 1 |
| Miyagawa, J | 1 |
| Namba, M | 1 |
| Salvadeo, SA | 1 |
| Ferrari, I | 1 |
| Ragonesi, PD | 1 |
| Gadaleta, G | 1 |
| Ciccarelli, L | 1 |
| Kirana, H | 1 |
| Srinivasan, BP | 1 |
| Kahn, SE | 2 |
| Lachin, JM | 1 |
| Zinman, B | 2 |
| Haffner, SM | 1 |
| Aftring, RP | 1 |
| Paul, G | 1 |
| Kravitz, BG | 1 |
| Herman, WH | 2 |
| Viberti, G | 2 |
| Holman, RR | 1 |
| Bianchi, L | 1 |
| Adeneye, AA | 1 |
| Agbaje, EO | 1 |
| Olagunju, JA | 1 |
| Agapova, SE | 1 |
| Vyas, AK | 1 |
| Boyda, HN | 1 |
| Procyshyn, RM | 1 |
| Tse, L | 1 |
| Hawkes, E | 1 |
| Jin, CH | 1 |
| Pang, CC | 1 |
| Honer, WG | 1 |
| Barr, AM | 1 |
| Nakamura, N | 1 |
| Fischer, S | 1 |
| Patzak, A | 1 |
| Rietzsch, H | 1 |
| Schwanebeck, U | 1 |
| Köhler, C | 1 |
| Wildbrett, J | 1 |
| Fuecker, K | 1 |
| Temelkova-Kurktschiev, T | 1 |
| Hanefeld, M | 2 |
| Bokhari, SU | 1 |
| Gopal, UM | 1 |
| Duckworth, WC | 1 |
| Tamás, G | 1 |
| Kerényi, Z | 1 |
| Tosi, F | 1 |
| Muggeo, M | 1 |
| Brun, E | 1 |
| Spiazzi, G | 1 |
| Perobelli, L | 1 |
| Zanolin, E | 1 |
| Gori, M | 1 |
| Coppini, A | 1 |
| Moghetti, P | 1 |
| Scheen, AJ | 1 |
| Yosefy, C | 1 |
| Magen, E | 1 |
| Kiselevich, A | 1 |
| Priluk, R | 1 |
| London, D | 1 |
| Volchek, L | 1 |
| Viskoper, RJ | 1 |
| Panikar, V | 1 |
| Chandalia, HB | 1 |
| Joshi, SR | 1 |
| Fafadia, A | 1 |
| Santvana, C | 1 |
| Tan, MH | 1 |
| Johns, D | 1 |
| Strand, J | 1 |
| Halse, J | 1 |
| Madsbad, S | 1 |
| Eriksson, JW | 1 |
| Clausen, J | 1 |
| Konkoy, CS | 1 |
| Herz, M | 1 |
| Putz, DM | 1 |
| Goldner, WS | 1 |
| Bar, RS | 1 |
| Haynes, WG | 1 |
| Sivitz, WI | 1 |
| Watanabe, I | 1 |
| Tani, S | 1 |
| Anazawa, T | 1 |
| Kushiro, T | 1 |
| Kanmatsuse, K | 1 |
| Inukai, K | 1 |
| Watanabe, M | 1 |
| Nakashima, Y | 1 |
| Sawa, T | 1 |
| Takata, N | 1 |
| Tanaka, M | 1 |
| Kashiwabara, H | 1 |
| Yokota, K | 1 |
| Suzuki, M | 1 |
| Kurihara, S | 1 |
| Awata, T | 2 |
| Katayama, S | 2 |
| Satoh, J | 1 |
| Takahashi, K | 1 |
| Takizawa, Y | 1 |
| Ishihara, H | 1 |
| Hirai, M | 1 |
| Katagiri, H | 1 |
| Hinokio, Y | 1 |
| Suzuki, S | 1 |
| Tsuji, I | 1 |
| Oka, Y | 1 |
| Chen, J | 2 |
| Jeppesen, PB | 1 |
| Abudula, R | 1 |
| Dyrskog, SE | 1 |
| Colombo, M | 1 |
| Hermansen, K | 1 |
| Koshiba, K | 1 |
| Nomura, M | 2 |
| Nakaya, Y | 2 |
| Ito, S | 2 |
| Monnier, L | 1 |
| Colette, C | 1 |
| Thuan, JF | 1 |
| Lapinski, H | 1 |
| Mori, Y | 1 |
| Itoh, Y | 1 |
| Obata, T | 1 |
| Tajima, N | 1 |
| Scollan-Koliopoulos, M | 1 |
| Guadagno, S | 1 |
| Walker, EA | 1 |
| Pfützner, A | 1 |
| Forst, T | 1 |
| Lübben, G | 1 |
| Taniguchi, Y | 1 |
| Ooie, T | 1 |
| Takahashi, N | 1 |
| Shinohara, T | 1 |
| Nakagawa, M | 1 |
| Yonemochi, H | 1 |
| Hara, M | 1 |
| Yoshimatsu, H | 1 |
| Saikawa, T | 1 |
| Harada, S | 1 |
| Lachin, J | 1 |
| Holman, R | 1 |
| Haffner, S | 1 |
| Kravitz, B | 1 |
| Heise, MA | 1 |
| Jones, NP | 1 |
| O'Neill, MC | 1 |
| Freed, MI | 1 |
| Chadwick, W | 1 |
| Wilson, G | 1 |
| van de Venter, M | 1 |
| Oelofsen, W | 1 |
| Roux, S | 1 |
| Atkinson, LL | 1 |
| McDonald-Dyck, C | 1 |
| Benkoczi, C | 1 |
| Finegood, DT | 1 |
| Cooper, MB | 1 |
| Al Majali, K | 1 |
| Bailey, CJ | 1 |
| Betteridge, DJ | 1 |
| Standl, E | 1 |
| Schnell, O | 1 |
| Kamgang, R | 1 |
| Mboumi, RY | 1 |
| Fondjo, AF | 1 |
| Tagne, MA | 1 |
| N'dillé, GP | 1 |
| Yonkeu, JN | 1 |
| Ao, Y | 1 |
| Yue, J | 1 |
| Peng, RX | 1 |
| Harano, Y | 1 |
| Ohgaku, S | 1 |
| Kosugi, K | 1 |
| Yasuda, H | 1 |
| Nakano, T | 1 |
| Kobayashi, M | 1 |
| Hidaka, H | 1 |
| Izumi, K | 1 |
| Kashiwagi, A | 1 |
| Shigeta, Y | 1 |
| Kolterman, OG | 1 |
| Prince, MJ | 1 |
| Olefsky, JM | 2 |
| Tattersall, RB | 1 |
| Birkeland, KI | 1 |
| Hanssen, KF | 1 |
| Urdal, P | 1 |
| Berg, K | 1 |
| Vaaler, S | 1 |
| Kumar, S | 1 |
| Boulton, AJ | 1 |
| Tak, PP | 1 |
| ten Kate, FJ | 1 |
| Jones, TW | 1 |
| Boulware, SD | 1 |
| Caprio, S | 1 |
| Merkel, P | 1 |
| Amiel, SA | 1 |
| Pearson, HA | 1 |
| Sherwin, RS | 1 |
| Tamborlane, WV | 1 |
| Wolffenbuttel, BH | 1 |
| Sels, JP | 1 |
| Rondas-Colbers, GJ | 1 |
| Menheere, PP | 1 |
| Kosegawa, I | 1 |
| Chen, S | 1 |
| Negishi, K | 1 |
| Chi, TC | 1 |
| Liu, IM | 1 |
| Cheng, JT | 1 |
| Taniguchi, A | 1 |
| Fukushima, M | 1 |
| Sakai, M | 1 |
| Tokuyama, K | 1 |
| Nagata, I | 1 |
| Fukunaga, A | 1 |
| Kishimoto, H | 1 |
| Doi, K | 1 |
| Yamashita, Y | 1 |
| Matsuura, T | 1 |
| Kitatani, N | 1 |
| Okumura, T | 1 |
| Nagasaka, S | 1 |
| Nakaishi, S | 1 |
| Nakai, Y | 1 |
| Sekiya, M | 1 |
| Suzuki, J | 1 |
| Watanabe, K | 1 |
| Funada, J | 1 |
| Otani, T | 1 |
| Akutsu, H | 1 |
| Miller, AW | 1 |
| Tulbert, C | 1 |
| Puskar, M | 1 |
| Busija, DW | 1 |
| Boyd, K | 1 |
| Rogers, C | 1 |
| Boreham, C | 1 |
| Andrews, WJ | 1 |
| Hadden, DR | 1 |
| Parillo, M | 1 |
| Rivellese, AA | 1 |
| Ciardullo, AV | 1 |
| Capaldo, B | 1 |
| Giacco, A | 1 |
| Genovese, S | 1 |
| Riccardi, G | 1 |
| Cortinovis, A | 1 |
| Crippa, A | 1 |
| Romano, E | 1 |
| Caro, JF | 1 |
| Khandekar, S | 1 |
| Sethi, BK | 1 |
| Dash, RJ | 1 |
| Chen, QM | 1 |
| Shank, WA | 1 |
| Morrison, AD | 1 |
| Draznin, B | 1 |
| Sussman, KE | 1 |
| Eckel, RH | 1 |
| Kao, M | 1 |
| Yost, T | 1 |
| Sherman, NA | 1 |
| Bolinder, J | 1 |
| Ostman, J | 1 |
| Arner, P | 1 |
| Owens, DR | 1 |
| Gavin, JR | 1 |
| Groop, L | 1 |
| Wåhlin-Boll, E | 1 |
| Groop, PH | 1 |
| Tötterman, KJ | 1 |
| Melander, A | 1 |
| Tolppanen, EM | 1 |
| Fyhrqvist, F | 1 |
| Hosker, JP | 1 |
| Burnett, MA | 1 |
| Davies, EG | 1 |
| Harris, EA | 1 |
| Turner, RC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT01947699] | Phase 4 | 0 participants (Actual) | Interventional | 2013-09-30 | Withdrawn (stopped due to PI decided to withdrawal study before recruitment started) | ||
| The Impact of Glucose Lowering Therapies Including Dipeptidyl Peptidase-4 Inhibitor on Circulating Endothelial Progenitor Cells (EPCs) and Its Mobilising Factor Stromal Derived Factor-1α (SDF-1α) in Patients With Type 2 Diabetes[NCT02694575] | 241 participants (Actual) | Observational | 2015-03-01 | Completed | |||
| A Randomized, Double-Blind Study to Compare the Durability of Glucose Lowering and Preservation of Pancreatic Beta-Cell Function of Rosiglitazone Monotherapy Compared to Metformin or Glyburide/Glibenclamide in Patients With Drug-Naive, Recently Diagnosed [NCT00279045] | Phase 3 | 4,426 participants (Actual) | Interventional | 2000-01-03 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
11 reviews available for glyburide and Insulin Resistance
| Article | Year |
|---|---|
[Effectiveness of phytotherapy in supportive treatment of type 2 diabetes mellitus II. Fenugreek (Trigonella foenum-graecum)].
Topics: Diabetes Mellitus, Type 2; Glucose; Glyburide; Humans; Hypoglycemic Agents; Insulin; Insulin Resista | 2015 |
Incretin-based drugs for type 2 diabetes: Focus on East Asian perspectives.
Topics: Animals; Asian People; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like | 2016 |
[Glimepiride].
Topics: Adenosine Triphosphate; Animals; ATP-Binding Cassette Transporters; Clinical Trials as Topic; Diabet | 2002 |
Current controversies in the mechanisms and treatment of gestational diabetes.
Topics: Autoimmune Diseases; Blood Glucose; Diabetes, Gestational; Female; Glyburide; Humans; Hypoglycemic A | 2002 |
[Medication of the month. Glucovance in type 2 diabetes, a fixed combination of metformin-glibenclamide for the treatment of a bipolar metabolic disease].
Topics: Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Glyburide; Humans; Hypoglycemic Agents; In | 2003 |
Gestational diabetes management: guidelines to a healthy pregnancy.
Topics: Diabetes Mellitus, Type 2; Diabetes, Gestational; Diet, Diabetic; Estrogens; Exercise; Female; Fetal | 2006 |
Insulin resistance in noninsulin-dependent diabetes mellitus: impact of sulfonylurea agents in vivo and in vitro.
Topics: Diabetes Mellitus; Glucose; Glyburide; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Rec | 1983 |
[25 years of diabetic treatment by oral hypoglycemic agents: successes and failures].
Topics: Aged; Aging; Blood Glucose; Cardiovascular Diseases; Chlorpropamide; Diabetes Complications; Diabete | 1984 |
Effects of glyburide on carbohydrate metabolism and insulin action in the liver.
Topics: Carbohydrate Metabolism; Diabetes Mellitus, Type 2; Glucose; Glyburide; Glycolysis; Humans; Insulin; | 1990 |
Oral sulfonylureas for the treatment of type II diabetes: an update.
Topics: Administration, Oral; Chlorpropamide; Diabetes Mellitus, Type 2; Drug Hypersensitivity; Glipizide; G | 1986 |
Effects of oral sulfonylureas on the spectrum of defects in non-insulin-dependent diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; Chlorpropamide; Clinical Trials as Topic; Combined Modality Therapy; Dia | 1985 |
31 trials available for glyburide and Insulin Resistance
| Article | Year |
|---|---|
Pharmacodynamics of Glyburide, Metformin, and Glyburide/Metformin Combination Therapy in the Treatment of Gestational Diabetes Mellitus.
Topics: Adolescent; Adult; Blood Glucose; Diabetes, Gestational; Drug Therapy, Combination; Female; Glyburid | 2020 |
The differential influence of glimepiride and glibenclamide on insulin resistance and adiponectin levels in patients with type 2 diabetes.
Topics: Adiponectin; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Hypoglycemic Agent | 2019 |
A comparison between sitagliptin or glibenclamide in addition to metformin + pioglitazone on glycaemic control and β-cell function: the triple oral therapy.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; F | 2013 |
A randomized, double-blind, comparative therapy evaluating sitagliptin versus glibenclamide in type 2 diabetes patients already treated with pioglitazone and metformin: a 3-year study.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; F | 2013 |
Are we optimizing gestational diabetes treatment with glyburide? The pharmacologic basis for better clinical practice.
Topics: Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Blood Glucose; Cytochrome P-450 CYP2C9; Diab | 2009 |
Exenatide versus glibenclamide in patients with diabetes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Body Mass Index; Body Weight; C-Reactive | 2010 |
Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT.
Topics: Aged; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Hypoglycemic Agents; Insulin Resistance; | 2011 |
Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load.
Topics: Administration, Oral; Biomarkers; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Female; G | 2011 |
Influence of treatment with acarbose or glibenclamide on insulin sensitivity in type 2 diabetic patients.
Topics: Acarbose; Adult; Aged; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Doubl | 2003 |
Beneficial effects of a glyburide/metformin combination preparation in type 2 diabetes mellitus.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Glyburide; Hemoglobin A; Humans; Hypogl | 2003 |
Combination treatment with metformin and glibenclamide versus single-drug therapies in type 2 diabetes mellitus: a randomized, double-blind, comparative study.
Topics: Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Bli | 2003 |
Rosiglitazone improves, while Glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity.
Topics: Administration, Oral; Albuminuria; Blood Glucose; Blood Pressure; Body Mass Index; Brachial Artery; | 2004 |
Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Hypoglycemic Agents; Insulin Re | 2004 |
Adiponectin and C-reactive protein in obesity, type 2 diabetes, and monodrug therapy.
Topics: Adiponectin; Blood Glucose; Body Composition; C-Reactive Protein; Cross-Over Studies; Diabetes Melli | 2004 |
Effect of pioglitazone on arteriosclerosis in comparison with that of glibenclamide.
Topics: Arteriosclerosis; Blood Glucose; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Administration Sc | 2005 |
Efficacy of glimepiride in Japanese type 2 diabetic subjects.
Topics: Aged; Asian People; Body Mass Index; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Fe | 2005 |
Secondary sulfonylurea failure: comparison of period until insulin treatment between diabetic patients treated with gliclazide and glibenclamide.
Topics: Age of Onset; Databases, Factual; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glic | 2005 |
Efficacy of glimepiride on insulin resistance, adipocytokines, and atherosclerosis.
Topics: Adipocytes; Aged; Atherosclerosis; Cytokines; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; | 2006 |
Effects of pioglitazone vs glibenclamide on postprandial increases in glucose and triglyceride levels and on oxidative stress in Japanese patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Fatty Acids, Nones | 2006 |
Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glyburide; Glycated Hemoglobin; Humans; Hypo | 2006 |
Nateglinide with glibenclamide examination using the respiratory quotient (RQ).
Topics: Aged; Blood Glucose; Body Weight; Cyclohexanes; Diabetes Mellitus, Type 2; Female; Glyburide; Humans | 2006 |
A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe.
Topics: Adult; Age Distribution; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Europe; Female; Glyburide; | 2006 |
Reduced postprandial proinsulinaemia and 32-33 split proinsulinaemia after a mixed meal in type 2 diabetic patients following sensitization to insulin with pioglitazone.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glyburide; Humans; Hyp | 2008 |
A long-term, randomized, comparative study of insulin versus sulfonylurea therapy in type 2 diabetes.
Topics: Aged; Blood Pressure; Diabetes Mellitus, Type 2; Female; Glucose Clamp Technique; Glyburide; Glycate | 1994 |
Effects of bezafibrate on insulin sensitivity and insulin secretion in non-obese Japanese type 2 diabetic patients.
Topics: Adult; Aged; Bezafibrate; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Hypog | 2001 |
Beneficial effect of troglitazone, an insulin-sensitizing antidiabetic agent, on coronary circulation in patients with non-insulin-dependent diabetes mellitus.
Topics: Adenosine Triphosphate; Aged; Blood Glucose; Case-Control Studies; Chromans; Coronary Circulation; D | 2001 |
Insulin, glibenclamide or metformin treatment for non insulin dependent diabetes: heterogenous responses of standard measures of insulin action and insulin secretion before and after differing hypoglycaemic therapy.
Topics: Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Glucose Clamp Technique; Glybu | 1992 |
A high-monounsaturated-fat/low-carbohydrate diet improves peripheral insulin sensitivity in non-insulin-dependent diabetic patients.
Topics: Adult; Blood Glucose; Body Mass Index; Combined Modality Therapy; Diabetes Mellitus, Type 2; Dietary | 1992 |
[Model of therapeutic programming in NIDDM diabetes].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glyburide; Humans; Hypoglycemic Agents; Insulin; Insulin R | 1992 |
Effects of oral sulfonylureas on the spectrum of defects in non-insulin-dependent diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; Chlorpropamide; Clinical Trials as Topic; Combined Modality Therapy; Dia | 1985 |
Pharmacokinetics and metabolic effects of glibenclamide and glipizide in type 2 diabetics.
Topics: Aged; Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Erythro | 1985 |
46 other studies available for glyburide and Insulin Resistance
| Article | Year |
|---|---|
Polypharmacology of N
Topics: Adenosine; Adenosine A3 Receptor Agonists; Adenosine A3 Receptor Antagonists; Adiponectin; Animals; | 2017 |
Effects of Securigera Securidaca seed extract in combination with glibenclamide on antioxidant capacity, fibroblast growth factor 21 and insulin resistance in hyperglycemic rats.
Topics: Animals; Antioxidants; Biomarkers; Blood Glucose; Diabetes Mellitus, Experimental; Drug Therapy, Com | 2020 |
Synthesis of a novel glibenclamide-pioglitazone hybrid compound and its effects on glucose homeostasis in normal and insulin-resistant rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Glyburide; Home | 2021 |
Hypoglycemic and Hypolipidemic Effects of Leucine, Zinc, and Chromium, Alone and in Combination, in Rats with Type 2 Diabetes.
Topics: Animals; Blood Glucose; Chromium; Combined Modality Therapy; Diabetes Mellitus, Type 2; Dietary Supp | 2017 |
Decreased insulin secretion in pregnant rats fed a low protein diet.
Topics: Animals; Arginine; Blood Glucose; Diet, Protein-Restricted; Dietary Proteins; Female; Glucose; Gluco | 2017 |
Antidiabetic drug glyburide modulates depressive-like behavior comorbid with insulin resistance.
Topics: Animals; Comorbidity; Depressive Disorder; Glyburide; Hypoglycemic Agents; Insulin Resistance; Male; | 2017 |
Emergence of insulin resistance following empirical glibenclamide therapy: a case report of neonatal diabetes with a recessive INS gene mutation.
Topics: Blood Glucose; Consanguinity; Diabetes Mellitus; Glyburide; Homozygote; Humans; Infant, Newborn; Inf | 2018 |
Contribution of systemic inflammation to permanence of K
Topics: Animals; Blood Glucose; Cytokines; Diabetes Mellitus; Glucagon; Glucagon-Like Peptide 1; Glyburide; | 2018 |
Fluvastatin causes NLRP3 inflammasome-mediated adipose insulin resistance.
Topics: 3T3-L1 Cells; Adipose Tissue; Animals; Carrier Proteins; Caspase 1; Fatty Acids, Monounsaturated; Fl | 2014 |
Isoliquiritigenin is a potent inhibitor of NLRP3 inflammasome activation and diet-induced adipose tissue inflammation.
Topics: Adipose Tissue, White; Animals; Anti-Inflammatory Agents; Carrier Proteins; Cell Line, Tumor; Chalco | 2014 |
Soluble epoxide hydrolase inhibition improves coronary endothelial function and prevents the development of cardiac alterations in obese insulin-resistant mice.
Topics: Animals; Benzoates; Blood Glucose; Coronary Vessels; Disease Models, Animal; Dose-Response Relations | 2015 |
Plausible anti-inflammatory mechanism of resveratrol and caffeic acid against chronic stress-induced insulin resistance in mice.
Topics: Animals; Anti-Inflammatory Agents; Blood Glucose; Caffeic Acids; Corticosterone; Cytokines; Drug The | 2016 |
Protective effects of Ficus carica leaves on glucose and lipids levels, carbohydrate metabolism enzymes and β-cells in type 2 diabetic rats.
Topics: Acetates; Animals; Biomarkers; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Ty | 2017 |
Glibenclamide treatment blocks metabolic dysfunctions and improves vagal activity in monosodium glutamate-obese male rats.
Topics: Adipose Tissue; Animals; Autonomic Nervous System; Blood Glucose; Body Weight; Eating; Glyburide; Hy | 2017 |
Effects of taurine on aortic rings isolated from fructose-fed insulin resistance Sprague-Dawley rat are changed.
Topics: 4-Aminopyridine; Acetylcholine; Administration, Oral; Animals; Aorta; Blood Glucose; Blood Pressure; | 2008 |
Effects of Glimepiride on metabolic parameters and cardiovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glyburide; Glycated Hemoglobin; Human | 2010 |
Effects of gliclazide on platelet aggregation and the plasminogen activator inhibitor type 1 level in patients with type 2 diabetes mellitus.
Topics: Aged; alpha-2-Antiplasmin; Antithrombin III; Azides; Blood Glucose; Body Mass Index; Deoxyuracil Nuc | 2010 |
Effect of Cyclea peltata Lam. roots aqueous extract on glucose levels, lipid profile, insulin, TNF-alpha and skeletal muscle glycogen in type 2 diabetic rats.
Topics: Animals; Blood Glucose; Cyclea; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Eva | 2010 |
Metformin: an effective attenuator of risperidone-induced insulin resistance hyperglycemia and dyslipidemia in rats.
Topics: Animals; Antipsychotic Agents; Blood Glucose; Disease Models, Animal; Dyslipidemias; Glyburide; Huma | 2011 |
Acute sulfonylurea therapy at disease onset can cause permanent remission of KATP-induced diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus; Glucose; Glyburide; Humans; Hypoglycemic Agents; Insulin | 2011 |
Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Female; Glucose Intolerance; Glyburide; Hypoglycemic | 2012 |
Beneficial effects of triple drug combination of pioglitazone with glibenclamide and metformin in type 2 diabetes mellitus patients on insulin therapy.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glyburide; Glycated Hemoglobin; Humans | 2003 |
Stevioside does not cause increased basal insulin secretion or beta-cell desensitization as does the sulphonylurea, glibenclamide: studies in vitro.
Topics: Animals; Diterpenes, Kaurane; Female; Glucose; Glucosides; Glyburide; Hypoglycemic Agents; In Vitro | 2006 |
[Hardly any hypoglycemias, constant weight--and still cost effective].
Topics: Body Weight; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drugs, Generic; Glyburide; Humans; Hy | 2005 |
Insulin secretion and sensitivity as determinants of HbA1c in type 2 diabetes.
Topics: Biomarkers; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glyburide; Glycated Hemogl | 2006 |
Pioglitazone but not glibenclamide improves cardiac expression of heat shock protein 72 and tolerance against ischemia/reperfusion injury in the heredity insulin-resistant rat.
Topics: Animals; Blotting, Western; Diabetes Mellitus, Type 2; Fever; Glucose Tolerance Test; Glyburide; HSP | 2006 |
Shifts in metabolic parameters surrounding glucose homoeostasis resulting from tricyclic antidepressant therapy: implications of insulin resistance?
Topics: Amitriptyline; Animals; Antidepressive Agents, Tricyclic; Blood Glucose; Cell Line; Glucose; Glyburi | 2007 |
Effect of chronic rosiglitazone, metformin and glyburide treatment on beta-cell mass, function and insulin sensitivity in mZDF rats.
Topics: Animals; Apoptosis; Blood Glucose; Glyburide; Hypoglycemic Agents; Insulin; Insulin Resistance; Insu | 2008 |
Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glyburide; Humans; Hypogl | 2008 |
Antihyperglycaemic potential of the water-ethanol extract of Kalanchoe crenata (Crassulaceae).
Topics: Administration, Oral; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Ty | 2008 |
Effects of 18alpha-glycyrrhizin on the pharmacodynamics and pharmacokinetics of glibenclamide in alloxan-induced diabetic rats.
Topics: Animals; Cytochrome P-450 CYP3A; Diabetes Mellitus, Experimental; Drug Interactions; Glyburide; Glyc | 2008 |
Clinical significance of altered insulin sensitivity in diabetes mellitus assessed by glucose, insulin, and somatostatin infusion.
Topics: Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus; Diet, Diabetic; Fasting; Glucose; Glyburi | 1981 |
Serious, prolonged hypoglycaemia with glibenclamide in a patient with Mendenhall's syndrome.
Topics: Abnormalities, Multiple; Adult; Diabetes Mellitus; Glyburide; Humans; Hyperplasia; Hypoglycemia; Hyp | 1993 |
Remission of active diabetic hepatitis after correction of hyperglycemia.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glyburide; Hepatitis; Humans; Hypergly | 1993 |
Correction of hyperinsulinemia by glyburide treatment in nondiabetic patients with thalassemia major.
Topics: Adolescent; Adult; beta-Thalassemia; Child; Diabetes Mellitus; Female; Glucose Tolerance Test; Glybu | 1993 |
Prognostic factors for successful insulin therapy in subjects with type 2 diabetes.
Topics: Aged; Biomarkers; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Drug Therapy, Combinati | 1999 |
Troglitazone and metformin, but not glibenclamide, decrease blood pressure in Otsuka Long Evans Tokushima Fatty rats.
Topics: Animals; Blood Glucose; Blood Pressure; Catecholamines; Chromans; Diabetes Mellitus, Type 2; Glucose | 1999 |
Less of insulin desensitization in sympathetic nerve terminals from wistar rats with insulin resistance.
Topics: Adipocytes; Adrenergic Fibers; Animals; Aorta; Blood Glucose; Carbon Radioisotopes; Deoxyglucose; Gl | 2000 |
Enhanced endothelin activity prevents vasodilation to insulin in insulin resistance.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Dose-Response Relationship, Drug; Endothelin Receptor Antagon | 2002 |
Effect of sulphonylurea therapy on insulin sensitivity in non insulin dependent diabetics.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glipizide; Glyburide; Humans; Insulin Resistance; Middle A | 1990 |
[Study on biological characteristics of spontaneous diabetic KK mice].
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Female; Glucose Tolerance Test; Glyburide; | 1988 |
Possible role of cytosolic free calcium concentrations in mediating insulin resistance of obesity and hyperinsulinemia.
Topics: Adipose Tissue; Adult; Biopsy; Calcium; Cytosol; Deoxyglucose; Female; Glyburide; Humans; Hyperinsul | 1988 |
Reversal of insulin resistance in adipose tissue of non-insulin-dependent diabetics by treatment with diet and sulphonylurea.
Topics: Adipose Tissue; Diabetes Mellitus, Type 2; Female; Glipizide; Glucose; Glyburide; Humans; Insulin; I | 1985 |
Clinical, cellular, and physiologic effects of glyburide in non-insulin-dependent diabetes mellitus.
Topics: Biological Transport; Diabetes Mellitus, Type 2; Drug Administration Schedule; Glucose; Glyburide; H | 1985 |
Dual actions of sulfonylureas and glyburide. Receptor and post-receptor effects.
Topics: Adipose Tissue; Animals; Cells, Cultured; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mel | 1985 |
Sulphonylurea therapy doubles B-cell response to glucose in type 2 diabetic patients.
Topics: Aged; Blood Glucose; C-Peptide; Chlorpropamide; Diabetes Mellitus, Type 2; Glucose; Glyburide; Human | 1985 |